ILMN logo
ILMN
Illumina

Next-generation Sequencing Will Expand Clinical Capabilities Despite Risks

AN
AnalystConsensusTarget
AnalystConsensusTarget
Not Invested
Consensus Narrative from 21 Analysts
Published
08 Aug 24
Updated
06 Aug 25
AnalystConsensusTarget's Fair Value
US$114.00
16.2% undervalued intrinsic discount
06 Aug
US$95.50
Loading
1Y
-24.6%
7D
-7.0%

Author's Valuation

US$114.0

16.2% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Narrative
Updates9

Shared on07 May 25
Fair value Decreased 0.14%

Read more

Shared on30 Apr 25
Fair value Decreased 3.00%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on23 Apr 25
Fair value Decreased 1.97%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on16 Apr 25
Fair value Decreased 4.17%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on09 Apr 25
Fair value Decreased 2.94%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on02 Apr 25
Fair value Decreased 1.59%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on26 Mar 25
Fair value Decreased 0.66%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on19 Mar 25
Fair value Increased 21%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on10 Mar 25
Fair value Increased 2.37%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more